| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)NCT04524858 | ACRS | Phase 2 | Terminated | 2021-02-25Actual |
| Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV)NCT04525157 | Clinuvel Pharmaceuticals Limited | Phase 2 | Completed | 2016-02-02Actual |
| Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of SchizophreniaNCT04531982 | ACAD | Phase 3 | Completed | 2024-01-25Actual |
| Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPFNCT04533022 | Vicore Pharma AB | Phase 2 | Completed | 2024-03-30Actual |
| Tafenoquine in Patients With Mild to Moderate COVID-19NCT04533347 | 60 Degrees Pharmaceuticals LLC | Phase 2 | Completed | 2022-06-30Actual |
| A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric CataractNCT04539548 | OCUL | Phase 3 | Completed | 2023-12-21Actual |
| Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)NCT04544293 | SVRA | Phase 3 | Active not recruiting | 2023-11-30Actual |
| A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAHNCT04544410 | Spruce Biosciences | Phase 2 | Terminated | 2024-10-31Actual |
| Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19NCT04551911 | OPK | Phase 2 | Completed | 2021-10-08Actual |
| Study of Selinexor in Combination With Ruxolitinib in MyelofibrosisNCT04562389 | KPTI | Phase 3 | Active not recruiting | 2026-02-20Actual |
| A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated MyelofibrosisNCT04562870 | KPTI | Phase 2 | Active not recruiting | 2026-09Estimated |
| A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)NCT04568434 | IONS | Phase 3 | Completed | 2023-07-14Actual |
| Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)NCT04569435 | ANNX | Phase 2 | Completed | 2024-01-10Actual |
| Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid LeukemiaNCT04571645 | Jazz Pharmaceuticals | Phase 3 | Terminated | 2022-05-16Actual |
| A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor TreatmentNCT04576156 | Geron Corporation | Phase 3 | Active not recruiting | 2028-06-30Estimated |
| A Study of Cytisinicline for Smoking Cessation in Adult SmokersNCT04576949 | Achieve Life Sciences | Phase 3 | Completed | 2021-12-23Actual |
| A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich AtaxiaNCT04577352 | PTC Therapeutics | Phase 2, Phase 3 | Completed | 2023-04-04Actual |
| A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)NCT04578548 | LKFT | Phase 2 | Terminated | 2022-12-14Actual |
| A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United KingdomNCT04583995 | Novavax | Phase 3 | Completed | 2022-03-29Actual |
| ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma MultiformeNCT04587830 | Polaris Group | Phase 2 | Active not recruiting | 2027-02-28Estimated |
| Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy VolunteersNCT04588428 | Inovio Pharmaceuticals | Phase 2 | Completed | 2023-01-19Actual |
| A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)NCT04592419 | KOD | Phase 3 | Completed | 2022-06-10Actual |
| A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's DiseaseNCT04592874 | ALEC | Phase 2 | Completed | 2024-08-19Actual |
| Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast CancerNCT04596150 | CytomX Therapeutics | Phase 2 | Completed | 2023-06-02Actual |
| Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic DermatitisNCT04598269 | ACRS | Phase 2 | Completed | 2021-04-08Actual |
| A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)NCT04602624 | SUPN | Phase 2 | Completed | 2021-09-28Actual |
| A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)NCT04603937 | KOD | Phase 3 | Terminated | 2023-04-27Actual |
| A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)NCT04611152 | KOD | Phase 3 | Terminated | 2023-05-11Actual |
| A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2NCT04611802 | Novavax | Phase 3 | Completed | 2023-04-10Actual |
| Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung CancerNCT04614103 | IOVA | Phase 2 | Recruiting | 2030-12Estimated |
Trial details
- Registry ID
- NCT04524858
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04525157
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04531982
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04533022
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04533347
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04539548
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04544293
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04544410
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04551911
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04562389
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04562870
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04568434
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04569435
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04571645
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04576156
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04576949
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04577352
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT04578548
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04583995
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04587830
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04588428
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04592419
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04592874
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04596150
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04598269
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04602624
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04603937
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04611152
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04611802
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04614103
- Phase
- Phase 2
Primary completion marks the end of data collection for the main study measures, not a results publication date.